Filing Flows › Vistagen Therapeutics (VTGN) › Q1 FY27
Vistagen Therapeutics (VTGN) Q1 FY27 earnings results (first quarter fiscal 2027)
10-Q filed Aug 14, 2026
Vistagen Therapeutics (VTGN) reported revenue of $1.5M for the first quarter fiscal 2027 (Q1 FY27), +505% from a year earlier and +217% from the quarter before. Operating margin was -904.3%, net loss $13.0M (882.8% of revenue).
Vistagen Therapeutics, Q1 FY27: revenue $1.5M (+505% year over year), operating margin -904.3%, net loss $13.0M, operating cash flow −$14.7M. The chart follows the revenue to costs, profit and cash.
| Q1 FY27 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | +217% | +505% |
| Operating profit | −$13.3M | — | — |
| Net earnings | −$13.0M | — | — |
| Operating cash flow | −$14.7M | — | — |
What changed
Revenue was $1.5M in Q1 FY27, up 505% year over year and up 217% from the previous quarter.
Operating costs exceeded revenue by $13.3M, an operating margin of -904.3%. Total costs fell 8% while revenue rose 505%. The quarter ended with a net loss of $13.0M, narrower than the previous quarter's $16.3M loss.
Operating cash flow was −$14.7M. Non-cash charges added back $52K of depreciation and amortization and $1.0M of share-based compensation. Working capital and other items used $2.7M.
Questions
What was Vistagen Therapeutics' revenue in the first quarter fiscal 2027?
Vistagen Therapeutics (VTGN) reported revenue of $1.5M for the first quarter fiscal 2027 (Q1 FY27), +505% from a year earlier and +217% from the quarter before.
Was Vistagen Therapeutics profitable in the first quarter fiscal 2027?
Operating loss was $13.3M (-904.3% of revenue) and net loss $13.0M.